Investing.com - Syros Pharma (NASDAQ: SYRS) reported third quarter EPS of $-1.430, $0.29 worse than the analyst estimate of $-1.140. Revenue for the quarter came in at $3.76M versus the consensus estimate of $3.94M.
Syros Pharma's stock price closed at $2.690. It is down -33.740% in the last 3 months and down -32.920% in the last 12 months.
Syros Pharma saw 3 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Syros Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Syros Pharma's Financial Health score is "fair performance".
Check out Syros Pharma's recent earnings performance, and Syros Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar